| Code | CSB-RA015057MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Emugrobart, targeting myostatin (MSTN), a negative regulator of skeletal muscle growth and development. MSTN, a member of the transforming growth factor-beta superfamily, functions by binding to activin type II receptors and inhibiting muscle protein synthesis through downstream SMAD signaling pathways. Under normal physiological conditions, MSTN maintains muscle mass homeostasis, but its dysregulation has been implicated in muscle-wasting disorders, sarcopenia, cachexia associated with chronic diseases, and muscular dystrophies. Elevated MSTN levels contribute to progressive muscle loss in conditions such as cancer cachexia, chronic obstructive pulmonary disease, and age-related sarcopenia.
Emugrobart represents a therapeutic antibody designed to neutralize MSTN activity, thereby promoting muscle growth and preventing muscle atrophy. This biosimilar antibody provides researchers with a valuable tool for investigating MSTN-mediated signaling pathways, exploring muscle regeneration mechanisms, and studying potential therapeutic interventions for muscle-wasting conditions. It supports investigations into metabolic disorders, neuromuscular diseases, and age-related muscle decline in preclinical research settings.
There are currently no reviews for this product.